FSGS
16
7
7
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
12.5%
2 terminated out of 16 trials
60.0%
-26.5% vs benchmark
25%
4 trials in Phase 3/4
133%
4 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (16)
NEPTUNE Match Study
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
A Study to Evaluate the Safety, Tolerability and PK of SK-09
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Atacicept in Multiple Glomerular Diseases
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
A Study of CCX140-B in Subjects With FSGS
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
Bortezomib for Treating Glomerular Diseases
Acthar for Treatment of Post-transplant FSGS
Rituximab to Prevent Recurrence of Proteinuria
A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients
The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis